01—Abstract
Summary
Summary of the 10-Q filed August 7, 2024. Cited figures are marked; the original filing is the authoritative source.
AbbVie Inc.'s second-quarter 2024 report shows continued revenue growth, with net revenues reaching $14.5 billiona, a 4.3% increase year-over-year.
This growth was primarily driven by strong performances in immunology (Skyrizi and Rinvoq) and neuroscience products like Vraylar and Qulipta. Despite an overall revenue increase, sales of key legacy products such as Humira and Imbruvica continued to decline due to biosimilar competition and market dynamics. Significant strategic moves during the period include the completion of the ImmunoGen acquisition for $9.2 billionb, strengthening AbbVie's oncology portfolio with antibody-drug conjugate capabilities.
The company also announced the subsequent acquisition of Cerevel Therapeutics for $8.7 billionc, further expanding its neuroscience pipeline. While net earnings decreased compared to the prior year, impacted by acquisition-related expenses and a change in fair value of contingent consideration, the company's operational execution and pipeline development remain strong. Investors should monitor the integration of ImmunoGen and the development of newly acquired assets, as well as the ongoing impact of biosimilar competition on established products.
02—Key points
Key Highlights
- AbbVie reported net revenues of $14.46 billion for Q2 2024, a 4.3% increase compared to $13.87 billion in Q2 2023.
- Net earnings attributable to AbbVie Inc. were $1.37 billion for Q2 2024, a decrease from $2.02 billion in Q2 2023, impacted by acquisition-related costs and changes in contingent consideration.
- The company completed the acquisition of ImmunoGen for approximately $9.8 billion, significantly enhancing its oncology franchise with ADC capabilities.
- Subsequent to the quarter, AbbVie announced the acquisition of Cerevel Therapeutics for approximately $8.7 billion to bolster its neuroscience pipeline.
- Immunology products Skyrizi and Rinvoq showed substantial growth, with revenues increasing by 44.8% and 55.8% respectively in Q2 2024.
- Sales of key products Humira and Imbruvica continued to decline, with Humira down 29.8% and Imbruvica down 8.2% in Q2 2024, reflecting ongoing market pressures.
- Diluted earnings per share were $0.77 for Q2 2024, down from $1.14 in Q2 2023.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2024, AbbVie Inc. kept $0.09.
- Revenue$14.46B100.0%
- Cost of revenue−$4.20B29.1%
- Gross profit$10.26B70.9%
- Operating costs−$6.26B43.3%
- Operating income$4.00B27.6%
- Interest, other & tax−$2.63B18.2%
- Net income$1.37B9.5%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2024filed August 7, 2024Financial Statements
Q2 FY2024 against Q2 FY2023
| Line item | Q2 FY2024Q2 FY2023 | Change |
|---|---|---|
| Revenue | $14.46B$13.87B | +4.3% |
| Cost of Revenue | $4.20B$4.24B | −0.9% |
| Gross Profit | $10.26B$9.63B | +6.6% |
| SG&A Expenses | $3.38B$3.27B | +3.3% |
| Operating Expenses | $10.46B$9.35B | +11.9% |
| Operating Income | $4.00B$4.51B | −11.4% |
| Interest Expense | $726.00M$552.00M | +31.5% |
| Net Income | $1.37B$2.02B | −32.3% |
| EPS (Basic) | $0.77$1.14 | −32.5% |
| EPS (Diluted) | $0.77$1.14 | −32.5% |
| Shares Outstanding (Basic) | 1.77B1.77B | +0.1% |
| Shares Outstanding (Diluted) | 1.77B1.77B | 0.0% |
05—Questions
Frequently Asked Questions
What was the financial performance of AbbVie in Q2 2024?
AbbVie reported net revenues of $14.46 billion for the three months ended June 30, 2024, an increase of 4.3% compared to $13.87 billion in the same period of 2023. Net earnings attributable to AbbVie Inc. were $1.37 billion, or $0.77 per diluted share, down from $2.02 billion, or $1.14 per diluted share, in the prior year. This decrease in earnings was primarily due to significant acquisition-related expenses, including costs associated with the ImmunoGen acquisition, and changes in the fair value of contingent consideration liabilities.
What are the key strategic developments mentioned in this filing?
The most significant strategic development is the completion of the acquisition of ImmunoGen, Inc. on February 12, 2024, for $9.2 billion, which strengthens AbbVie's oncology pipeline, particularly in antibody-drug conjugates (ADCs). Additionally, subsequent to the quarter end (on August 1, 2024), AbbVie announced the completion of its acquisition of Cerevel Therapeutics for approximately $8.7 billion, further expanding its neuroscience drug development capabilities. These acquisitions highlight AbbVie's commitment to strategic growth through portfolio expansion.
How are AbbVie's key growth drivers performing, and what is the impact on legacy products?
AbbVie's key growth drivers, Skyrizi and Rinvoq in immunology, continue to perform exceptionally well, with revenues increasing by 44.8% and 55.8% respectively in the second quarter of 2024. Neuroscience products like Vraylar and Qulipta also demonstrated strong growth. However, sales of legacy products like Humira and Imbruvica are declining, with Humira revenues down 29.8% and Imbruvica down 8.2% year-over-year, largely due to biosimilar competition and market dynamics, particularly for Humira in the U.S.
What is the company's financial outlook and capital allocation strategy?
AbbVie generated $6.3 billion in cash flows from operating activities for the first six months of 2024. The company is focused on investing in its pipeline, returning cash to shareholders through dividends and share repurchases, and repaying debt. The company recently issued $15 billion in senior notes to finance acquisitions and other corporate purposes. AbbVie also declared a quarterly cash dividend of $1.55 per share and has an ongoing stock repurchase authorization with approximately $3.9 billion remaining as of June 30, 2024.
06—Continue